Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator
Summary Platinum(II) metallointercalators represent a new class of DNA-damaging antitumor complexes active in cisplatin- and oxaliplatin-resistant cell lines. In the first part of our work, we have screened in vitro a serie of 18 metallointercalators with the structure [Pt(A L )(I L )] 2+ where A L...
Gespeichert in:
| Veröffentlicht in: | Investigational new drugs 2011-12, Vol.29 (6), p.1164-1176 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1176 |
|---|---|
| container_issue | 6 |
| container_start_page | 1164 |
| container_title | Investigational new drugs |
| container_volume | 29 |
| creator | Moretto, Johnny Chauffert, Bruno Ghiringhelli, François Aldrich-Wright, Janice R. Bouyer, Florence |
| description | Summary
Platinum(II) metallointercalators represent a new class of DNA-damaging antitumor complexes active in cisplatin- and oxaliplatin-resistant cell lines. In the first part of our work, we have screened in vitro a serie of 18 metallointercalators with the structure [Pt(A
L
)(I
L
)]
2+
where A
L
= ethylenediamine (EN) or diaminocyclohexane in
R,R-
(RR) or
S,S-
(SS) configuration ; and I
L
= 1,10-phenanthroline with different degree of methylation : no methylation (PHEN), mono-methylated in position 4 (4ME) or 5 (5ME), or di-methylated in positions 4 and 7 (47ME) or in positions 5 and 6 (56ME) or tetramethylated in positions 3,4,7 and 8 (3478ME). Eight compounds: PHENEN, 56MEEN, 47MERR, 56MERR, 4MESS, 5MESS, 47MESS and 56MESS exhibited significant cytotoxic effect, equivalent or higher than cisplatin, oxaliplatin or carboplatin in the human HCT8 colon and IGROV1 ovarian cancer cell lines for both 1 and 24 h incubation time. The high cytotoxicity of the most active compound, the 56MESS, could be related to the hydrophobicity of the phenanthroline ligand that increases cellular uptake in human HCT8, HT29 (colon) and IGROV1 (ovarian) as well as in rat PROb colon cell lines. Unfortunately, intravenous or intraperitoneal administration of 56MESS had no antitumoral activity in BD-IX rats with peritoneal carcinomatosis induced by an intraperitoneal PROb cells inoculation. Moreover, 56MESS displayed nephrotoxicity at pharmacological dose. Thus, these data query the in vivo
/
in vitro correlation and reconsider the place of the in vivo screening to select adequate candidate drug for further preclinical and clinical developments. |
| doi_str_mv | 10.1007/s10637-010-9461-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1468377114</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2789204741</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-db52dc5733ed7f0f4e295346f7b63ab1e23f49c862f07fcb3df798a02b8cb2793</originalsourceid><addsrcrecordid>eNp1kUFvFSEUhYnR2Gf1B7gxJG7qYpQLDMwsTW31JU26qWvCMBczzQw8gWnT_np5mWqMiSsg57vn3ssh5C2wj8CY_pSBKaEbBqzppYLm8RnZQatFw5RUz8mOgdKN6nt9Ql7lfMsYE72WL8kJZ61oW652xH2Zskt4sME90AHLPWKgU6B3U0mR2jBuj7vjvUxlXWKi6D26QqOnlga8p4fZlimsy9l-_4EuWOw8xykUTM5WJabX5IW3c8Y3T-cp-X55cXP-rbm6_ro__3zVOMlkacah5aOr4wsctWdeIu9bIZXXgxJ2AOTCy951inumvRvE6HXfWcaHzg1c9-KUnG2-hxR_rpiLWepyOM82YFyzAak6oTWArOj7f9DbuKZQpzMAwEFw6KBSsFEuxZwTenNI02LTgwFmjgmYLQFTEzDHBMxjrXn35LwOC45_Kn5_eQX4BuQqhR-Y_mr9X9df-X-RwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1112132181</pqid></control><display><type>article</type><title>Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator</title><source>MEDLINE</source><source>Springer Journals</source><creator>Moretto, Johnny ; Chauffert, Bruno ; Ghiringhelli, François ; Aldrich-Wright, Janice R. ; Bouyer, Florence</creator><creatorcontrib>Moretto, Johnny ; Chauffert, Bruno ; Ghiringhelli, François ; Aldrich-Wright, Janice R. ; Bouyer, Florence</creatorcontrib><description>Summary
Platinum(II) metallointercalators represent a new class of DNA-damaging antitumor complexes active in cisplatin- and oxaliplatin-resistant cell lines. In the first part of our work, we have screened in vitro a serie of 18 metallointercalators with the structure [Pt(A
L
)(I
L
)]
2+
where A
L
= ethylenediamine (EN) or diaminocyclohexane in
R,R-
(RR) or
S,S-
(SS) configuration ; and I
L
= 1,10-phenanthroline with different degree of methylation : no methylation (PHEN), mono-methylated in position 4 (4ME) or 5 (5ME), or di-methylated in positions 4 and 7 (47ME) or in positions 5 and 6 (56ME) or tetramethylated in positions 3,4,7 and 8 (3478ME). Eight compounds: PHENEN, 56MEEN, 47MERR, 56MERR, 4MESS, 5MESS, 47MESS and 56MESS exhibited significant cytotoxic effect, equivalent or higher than cisplatin, oxaliplatin or carboplatin in the human HCT8 colon and IGROV1 ovarian cancer cell lines for both 1 and 24 h incubation time. The high cytotoxicity of the most active compound, the 56MESS, could be related to the hydrophobicity of the phenanthroline ligand that increases cellular uptake in human HCT8, HT29 (colon) and IGROV1 (ovarian) as well as in rat PROb colon cell lines. Unfortunately, intravenous or intraperitoneal administration of 56MESS had no antitumoral activity in BD-IX rats with peritoneal carcinomatosis induced by an intraperitoneal PROb cells inoculation. Moreover, 56MESS displayed nephrotoxicity at pharmacological dose. Thus, these data query the in vivo
/
in vitro correlation and reconsider the place of the in vivo screening to select adequate candidate drug for further preclinical and clinical developments.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/s10637-010-9461-z</identifier><identifier>PMID: 20535526</identifier><identifier>CODEN: INNDDK</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Animals ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - toxicity ; Cancer therapies ; Cell Line, Tumor ; Colon ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - pathology ; Cytotoxicity ; DNA methylation ; Drug dosages ; Drug Screening Assays, Antitumor - methods ; Female ; Humans ; Hydrophobic and Hydrophilic Interactions ; Intercalating Agents - chemistry ; Intercalating Agents - pharmacology ; Intercalating Agents - toxicity ; Investigations ; Laboratories ; Ligands ; Male ; Medicine ; Medicine & Public Health ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Peritoneal Neoplasms - drug therapy ; Peritoneal Neoplasms - pathology ; Pharmacology ; Pharmacology/Toxicology ; Platinum ; Platinum Compounds - chemistry ; Platinum Compounds - pharmacology ; Platinum Compounds - toxicity ; Preclinical Studies ; Rats ; Structure-Activity Relationship ; Studies ; Time Factors</subject><ispartof>Investigational new drugs, 2011-12, Vol.29 (6), p.1164-1176</ispartof><rights>Springer Science+Business Media, LLC 2010</rights><rights>Springer Science+Business Media, LLC 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-db52dc5733ed7f0f4e295346f7b63ab1e23f49c862f07fcb3df798a02b8cb2793</citedby><cites>FETCH-LOGICAL-c404t-db52dc5733ed7f0f4e295346f7b63ab1e23f49c862f07fcb3df798a02b8cb2793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10637-010-9461-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10637-010-9461-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20535526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moretto, Johnny</creatorcontrib><creatorcontrib>Chauffert, Bruno</creatorcontrib><creatorcontrib>Ghiringhelli, François</creatorcontrib><creatorcontrib>Aldrich-Wright, Janice R.</creatorcontrib><creatorcontrib>Bouyer, Florence</creatorcontrib><title>Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><addtitle>Invest New Drugs</addtitle><description>Summary
Platinum(II) metallointercalators represent a new class of DNA-damaging antitumor complexes active in cisplatin- and oxaliplatin-resistant cell lines. In the first part of our work, we have screened in vitro a serie of 18 metallointercalators with the structure [Pt(A
L
)(I
L
)]
2+
where A
L
= ethylenediamine (EN) or diaminocyclohexane in
R,R-
(RR) or
S,S-
(SS) configuration ; and I
L
= 1,10-phenanthroline with different degree of methylation : no methylation (PHEN), mono-methylated in position 4 (4ME) or 5 (5ME), or di-methylated in positions 4 and 7 (47ME) or in positions 5 and 6 (56ME) or tetramethylated in positions 3,4,7 and 8 (3478ME). Eight compounds: PHENEN, 56MEEN, 47MERR, 56MERR, 4MESS, 5MESS, 47MESS and 56MESS exhibited significant cytotoxic effect, equivalent or higher than cisplatin, oxaliplatin or carboplatin in the human HCT8 colon and IGROV1 ovarian cancer cell lines for both 1 and 24 h incubation time. The high cytotoxicity of the most active compound, the 56MESS, could be related to the hydrophobicity of the phenanthroline ligand that increases cellular uptake in human HCT8, HT29 (colon) and IGROV1 (ovarian) as well as in rat PROb colon cell lines. Unfortunately, intravenous or intraperitoneal administration of 56MESS had no antitumoral activity in BD-IX rats with peritoneal carcinomatosis induced by an intraperitoneal PROb cells inoculation. Moreover, 56MESS displayed nephrotoxicity at pharmacological dose. Thus, these data query the in vivo
/
in vitro correlation and reconsider the place of the in vivo screening to select adequate candidate drug for further preclinical and clinical developments.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - toxicity</subject><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Colon</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - pathology</subject><subject>Cytotoxicity</subject><subject>DNA methylation</subject><subject>Drug dosages</subject><subject>Drug Screening Assays, Antitumor - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Intercalating Agents - chemistry</subject><subject>Intercalating Agents - pharmacology</subject><subject>Intercalating Agents - toxicity</subject><subject>Investigations</subject><subject>Laboratories</subject><subject>Ligands</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Peritoneal Neoplasms - drug therapy</subject><subject>Peritoneal Neoplasms - pathology</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Platinum</subject><subject>Platinum Compounds - chemistry</subject><subject>Platinum Compounds - pharmacology</subject><subject>Platinum Compounds - toxicity</subject><subject>Preclinical Studies</subject><subject>Rats</subject><subject>Structure-Activity Relationship</subject><subject>Studies</subject><subject>Time Factors</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kUFvFSEUhYnR2Gf1B7gxJG7qYpQLDMwsTW31JU26qWvCMBczzQw8gWnT_np5mWqMiSsg57vn3ssh5C2wj8CY_pSBKaEbBqzppYLm8RnZQatFw5RUz8mOgdKN6nt9Ql7lfMsYE72WL8kJZ61oW652xH2Zskt4sME90AHLPWKgU6B3U0mR2jBuj7vjvUxlXWKi6D26QqOnlga8p4fZlimsy9l-_4EuWOw8xykUTM5WJabX5IW3c8Y3T-cp-X55cXP-rbm6_ro__3zVOMlkacah5aOr4wsctWdeIu9bIZXXgxJ2AOTCy951inumvRvE6HXfWcaHzg1c9-KUnG2-hxR_rpiLWepyOM82YFyzAak6oTWArOj7f9DbuKZQpzMAwEFw6KBSsFEuxZwTenNI02LTgwFmjgmYLQFTEzDHBMxjrXn35LwOC45_Kn5_eQX4BuQqhR-Y_mr9X9df-X-RwA</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Moretto, Johnny</creator><creator>Chauffert, Bruno</creator><creator>Ghiringhelli, François</creator><creator>Aldrich-Wright, Janice R.</creator><creator>Bouyer, Florence</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0C</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20111201</creationdate><title>Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator</title><author>Moretto, Johnny ; Chauffert, Bruno ; Ghiringhelli, François ; Aldrich-Wright, Janice R. ; Bouyer, Florence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-db52dc5733ed7f0f4e295346f7b63ab1e23f49c862f07fcb3df798a02b8cb2793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - toxicity</topic><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Colon</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - pathology</topic><topic>Cytotoxicity</topic><topic>DNA methylation</topic><topic>Drug dosages</topic><topic>Drug Screening Assays, Antitumor - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Intercalating Agents - chemistry</topic><topic>Intercalating Agents - pharmacology</topic><topic>Intercalating Agents - toxicity</topic><topic>Investigations</topic><topic>Laboratories</topic><topic>Ligands</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Peritoneal Neoplasms - drug therapy</topic><topic>Peritoneal Neoplasms - pathology</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Platinum</topic><topic>Platinum Compounds - chemistry</topic><topic>Platinum Compounds - pharmacology</topic><topic>Platinum Compounds - toxicity</topic><topic>Preclinical Studies</topic><topic>Rats</topic><topic>Structure-Activity Relationship</topic><topic>Studies</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moretto, Johnny</creatorcontrib><creatorcontrib>Chauffert, Bruno</creatorcontrib><creatorcontrib>Ghiringhelli, François</creatorcontrib><creatorcontrib>Aldrich-Wright, Janice R.</creatorcontrib><creatorcontrib>Bouyer, Florence</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global (ProQuest)</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moretto, Johnny</au><au>Chauffert, Bruno</au><au>Ghiringhelli, François</au><au>Aldrich-Wright, Janice R.</au><au>Bouyer, Florence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator</atitle><jtitle>Investigational new drugs</jtitle><stitle>Invest New Drugs</stitle><addtitle>Invest New Drugs</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>29</volume><issue>6</issue><spage>1164</spage><epage>1176</epage><pages>1164-1176</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><coden>INNDDK</coden><abstract>Summary
Platinum(II) metallointercalators represent a new class of DNA-damaging antitumor complexes active in cisplatin- and oxaliplatin-resistant cell lines. In the first part of our work, we have screened in vitro a serie of 18 metallointercalators with the structure [Pt(A
L
)(I
L
)]
2+
where A
L
= ethylenediamine (EN) or diaminocyclohexane in
R,R-
(RR) or
S,S-
(SS) configuration ; and I
L
= 1,10-phenanthroline with different degree of methylation : no methylation (PHEN), mono-methylated in position 4 (4ME) or 5 (5ME), or di-methylated in positions 4 and 7 (47ME) or in positions 5 and 6 (56ME) or tetramethylated in positions 3,4,7 and 8 (3478ME). Eight compounds: PHENEN, 56MEEN, 47MERR, 56MERR, 4MESS, 5MESS, 47MESS and 56MESS exhibited significant cytotoxic effect, equivalent or higher than cisplatin, oxaliplatin or carboplatin in the human HCT8 colon and IGROV1 ovarian cancer cell lines for both 1 and 24 h incubation time. The high cytotoxicity of the most active compound, the 56MESS, could be related to the hydrophobicity of the phenanthroline ligand that increases cellular uptake in human HCT8, HT29 (colon) and IGROV1 (ovarian) as well as in rat PROb colon cell lines. Unfortunately, intravenous or intraperitoneal administration of 56MESS had no antitumoral activity in BD-IX rats with peritoneal carcinomatosis induced by an intraperitoneal PROb cells inoculation. Moreover, 56MESS displayed nephrotoxicity at pharmacological dose. Thus, these data query the in vivo
/
in vitro correlation and reconsider the place of the in vivo screening to select adequate candidate drug for further preclinical and clinical developments.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>20535526</pmid><doi>10.1007/s10637-010-9461-z</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6997 |
| ispartof | Investigational new drugs, 2011-12, Vol.29 (6), p.1164-1176 |
| issn | 0167-6997 1573-0646 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1468377114 |
| source | MEDLINE; Springer Journals |
| subjects | Animals Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antineoplastic Agents - toxicity Cancer therapies Cell Line, Tumor Colon Colonic Neoplasms - drug therapy Colonic Neoplasms - pathology Cytotoxicity DNA methylation Drug dosages Drug Screening Assays, Antitumor - methods Female Humans Hydrophobic and Hydrophilic Interactions Intercalating Agents - chemistry Intercalating Agents - pharmacology Intercalating Agents - toxicity Investigations Laboratories Ligands Male Medicine Medicine & Public Health Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - pathology Pharmacology Pharmacology/Toxicology Platinum Platinum Compounds - chemistry Platinum Compounds - pharmacology Platinum Compounds - toxicity Preclinical Studies Rats Structure-Activity Relationship Studies Time Factors |
| title | Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T18%3A41%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discrepancy%20between%20in%20vitro%20and%20in%20vivo%20antitumor%20effect%20of%20a%20new%20platinum(II)%20metallointercalator&rft.jtitle=Investigational%20new%20drugs&rft.au=Moretto,%20Johnny&rft.date=2011-12-01&rft.volume=29&rft.issue=6&rft.spage=1164&rft.epage=1176&rft.pages=1164-1176&rft.issn=0167-6997&rft.eissn=1573-0646&rft.coden=INNDDK&rft_id=info:doi/10.1007/s10637-010-9461-z&rft_dat=%3Cproquest_cross%3E2789204741%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1112132181&rft_id=info:pmid/20535526&rfr_iscdi=true |